Table 2.
Characteristics of patients according to the fulfilment of the 2019 IgG4-related disease ACR/EULAR classification criteria
| Meets 2019 IgG4-RD ACR/EULAR classification criteria |
||||
|---|---|---|---|---|
| No (n = 24) | Yes (n = 81) | P-value | Total (n = 105) | |
| Age at diagnosis, mean (s.d.), years | 55.5 (15.1) | 55.3 (13.5) | 1.0 | 55.4 (13.8) |
| Female, % (n) | 21 (5) | 37 (30) | 0.1 | 33 (35) |
| White, % (n) | 100 (24) | 79 (64) | 0.01 | 84 (88) |
| North African/Middle East, % (n) | 0 (0) | 6 (5) | 0.6 | 5 (5) |
| Hispanic, % (n) | 0 (0) | 15 (12) | 0.06 | 11 (12) |
| Biopsy, % (n) | 79 (19) | 96 (78) | 0.01 | 92 (97) |
| Pathology standard, % (n) | 42 (8) | 79 (62) | 0.001 | 72 (70) |
| Elevated serum IgG4, % (n) | 58 (14) | 37 (30) | 0.06 | 42 (44) |
| IPC, % (n) | 62 (15) | 93 (75) | <0.001 | 86 (90) |
| Highly suggestive, % (n) | 33 (8) | 65 (53) | 0.005 | 58 (61) |
| Probable, % (n) | 29 (7) | 27 (22) | 0.8 | 28 (29) |
| JCC, % (n) | 96 (23) | 94 (76) | 1.0 | 94 (99) |
| Definite, % (n) | 25 (6) | 35 (28) | 0.4 | 32 (34) |
| Probable, % (n) | 33 (8) | 49 (40) | 0.2 | 46 (48) |
| Possible, % (n) | 38 (9) | 10 (8) | 0.003 | 16 (17) |
| Systemic, % (n) | 46 (11) | 52 (42) | 0.6 | 50 (53) |
| Pancreas, % (n) | 12 (3) | 15 (12) | 1.0 | 14 (15) |
| Lacrimal glands, % (n) | 4 (1) | 9 (7) | 0.7 | 8 (8) |
| Orbit, % (n) | 12 (3) | 19 (15) | 0.8 | 17 (18) |
| Extraocular muscles, % (n) | 4 (1) | 7 (6) | 1.0 | 7 (7) |
| Salivary glands, % (n) | 17 (4) | 15 (12) | 0.8 | 15 (16) |
| Pachymeninges, % (n) | 4 (1) | 5 (4) | 1.0 | 5 (5) |
| Hypophysis, % (n) | 0 (0) | 1 (1) | 1.0 | 1 (1) |
| Thyroid, % (n) | 0 (0) | 4 (3) | 1.0 | 3 (3) |
| Aorta, % (n) | 12 (3) | 12 (10) | 1.0 | 12 (13) |
| Arteries, % (n) | 0 (0) | 5 (4) | 0.6 | 4 (4) |
| Mediastinum, % (n) | 0 (0) | 6 (5) | 0.6 | 5 (5) |
| Retroperitoneum, % (n) | 25 (6) | 38 (31) | 0.2 | 35 (37) |
| Mesenterium, % (n) | 8 (2) | 6 (5) | 0.7 | 7 (7) |
| Skin, % (n) | 0 (0) | 2 (2) | 1.0 | 2 (2) |
| Lymph nodes, % (n) | 21 (5) | 20 (16) | 1.0 | 20 (21) |
| Biliary ducts, % (n) | 12 (3) | 2 (2) | 0.08 | 5 (5) |
| Gallbladder, % (n) | 0 (0) | 4 (3) | 1.0 | 3 (3) |
| Liver, % (n) | 0 (0) | 4 (3) | 1.0 | 3 (3) |
| Lung, % (n) | 17 (4) | 7 (6) | 0.2 | 10 (10) |
| Pleura, % (n) | 12 (3) | 2 (2) | 0.08 | 5 (5) |
| Pericardium, % (n) | 4 (1) | 4 (3) | 1.0 | 4 (4) |
| Kidney, % (n) | 0 (0) | 10 (7) | 0.3 | 7 (7) |
| Breast, % (n) | 0 (0) | 1 (1) | 1.0 | 1 (1) |
| Prostate, % (n) | 0 (0) | 1 (1) | 1.0 | 1 (1) |
| Maxillary sinus, % (n) | 17 (4) | 9 (7) | 0.3 | 10 (11) |
| Other organs, % (n) | 8 (2) | 10 (8) | 0.7 | 10 (10) |
Dichotomous variables are expressed as percentage (count) and continuous variables as mean (s.d.). Bivariate comparisons of continuous variables were made using Student’s t-test while bivariate comparisons of dichotomous variables were made either using χ2 test or Fisher’s exact test, as appropriate. IgG4: immunoglobulin G 4; IgG4-RD ACR/EULAR: IgG4-related disease American College of Rheumatology/European League Against Rheumatism; IPC: international pathology criteria; JCC: Japanese comprehensive criteria.